CI Global Health Sciences Corporate Class

Series P USD
 

Fund overview

This fund invests primarily in equity and equity-related securities of companies around the world that specialize in the health care or medical industry.

Fund details

description of elementelement value
Inception date May 2017
CAD Total net assets ($CAD)
As at 2026-01-30
$149.2 million
NAVPS
As at 2026-02-13
$9.5421
MER (%)
As at 2025-09-30
0.24
Management fee (%) 0.90
Asset class Sector Equity
Currency USD
Minimum investment $500 initial/$25 additional
Distribution frequency Quarterly
Last distribution $0.1669

Risk rating1

  • Low
  • Low to medium
  • Medium
  • Medium to high
  • High

FUND CODES

P 90324
A ISC 301
DSC SO* 401
LL SO 1401
F 324
*No new purchases directly into switch only funds.

Performance2 As at 2026-01-31

Growth of $10,000 (Since inception date)

growth of 10k graph

Calendar year performance

annual performance graph

average annual compound returns

YTD 1 Mo 3 Mo 6 Mo 1 Y 3 Y 5 Y 10 Y Inception*
-0.01% -0.01% 7.20% 19.08% 3.74% 4.44% 1.47% - 5.15%
*Since inception date

Distribution history3

Payable date Total
2022-03-25 0.1669
2021-03-26 0.0563
2020-12-18 0.0892
2020-09-25 0.0844
2020-06-26 0.0615
Payable date Total
2020-03-20 0.1428
2019-12-13 0.0890
2019-09-27 0.0991
2019-06-21 0.0930
2019-03-22 0.1458

Management team

First we'll display the Team Company and then the Team members
Greg Quickmire
Peter Hofstra

CI Global Health Sciences Corporate Class

Series P USD
 
Portfolio allocations4 As at 2026-01-31
Asset allocation (%)
  • US Equity 81.07
  • International Equity 17.33
  • Cash and Equivalents 1.58
  • Other 0.02
Sector allocation (%)
  • Healthcare 95.22
  • Exchange Traded Fund 3.18
  • Cash and Cash Equivalent 1.58
  • Other 0.02
Geographic allocation(%)
  • United States 81.35
  • United Kingdom 9.48
  • Switzerland 7.12
  • Canada 1.26
  • Netherlands 0.77
  • Other 0.02
Top holdings5
Sector (%)
1. Eli Lilly and Co Drugs 14.11%
2. AstraZeneca PLC Drugs 9.48%
3. DexCom Inc Healthcare Equipment 8.40%
4. Thermo Fisher Scientific Inc Healthcare Equipment 6.97%
5. Johnson & Johnson Drugs 6.59%
6. Stryker Corp Healthcare Equipment 6.30%
7. Danaher Corp Healthcare Equipment 5.73%
8. IQVIA Holdings Inc Drugs 5.08%
9. Boston Scientific Corp Healthcare Equipment 4.90%
10. Intuitive Surgical Inc Healthcare Equipment 4.41%
11. Vertex Pharmaceuticals Inc Drugs 4.27%
12. Roche Holding AG - Partcptn Drugs 3.74%
13. Merck & Co Inc Drugs 3.33%
14. SPDR S&P Biotech ETF (XBI) Exchange Traded Fund 3.18%
15. AbbVie Inc Drugs 3.10%
Over 35,000 financial advisors have chosen CI Global Asset Management as a partner. We believe that Canadians have the best opportunity for investments success by using the services of a professional financial advisor. Learn more at ci.com.